Drug Profile

YA 101

Alternative Names: YA-101

Latest Information Update: 06 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yoda Pharmaceuticals
Developer Dasher Neuroscience
Class Anti-inflammatories
Mechanism of Action D amino acid oxidase inhibitors; Neuronal plasticity modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple system atrophy
New Molecular Entity Yes

Highest Development Phases

Phase II Multiple system atrophy

Most Recent Events

06 Aug 2026 Dasher Neuroscience plans a phase III trial for Multiple system atrophy (PO)
28 Jul 2026 YA 101 receives Fast Track designation for Multiple system atrophy [PO] in USA
28 Jul 2026 YA 101 receives Orphan Drug status for Multiple system atrophy in European Union

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com